MAINZ, Germany, May 27, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data from select pipeline candidates across the Company’s diversified oncology ...
In the second quarter, the firm began dosing patients in three signal-seeking clinical trials to evaluate BNT327, its VEGF x PD-L1 bispecific, in combination with antibody-drug conjugates as ...
Pumitamig data from the ongoing Phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer mark the third global data set to consistently show encouraging anti-tumor activity for ...
The disconnect between BioNTech’s clinical achievements and its stock price has rarely been starker. While the Mainz-based biotech presented encouraging oncology data at this year’s ASCO conference, ...
Hosted on MSN
BioNTech’s Earnings Call: Progress Amid Challenges
Biontech Se Sponsored Adr ((BNTX)) has held its Q3 earnings call. Read on for the main highlights of the call. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced ...
With much riding on its mRNA patent litigation against BioNTech, Germany’s CureVac thinks the case is moving in its favor. But the company's investors didn't join in on the celebrations Thursday. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results